{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-121180","form_type":"8-K","ticker":"BTAI","cik":"0001720893","company_name":"BioXcel Therapeutics, Inc.","filed_at":"2025-12-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.251543+00:00","generated_at":"2026-05-16T13:14:14.232210+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"BioXcel stockholders approve reverse stock split authorization and elect directors","bullets":["All five proposals passed at Dec 12 annual meeting; 44.68% of shares voted.","Directors June Bray, Sandeep Laumas, David Mack elected as Class I directors.","Ernst & Young ratified as independent auditor for FY2025.","Advisory say-on-pay approved with ~78% of votes cast (excl. broker non-votes).","Stockholders authorized reverse stock split of 1:2 to 1:20 to regain Nasdaq bid price compliance."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-121180","json":"https://secwatch.observer/filing/0001104659-25-121180.json","markdown":"https://secwatch.observer/filing/0001104659-25-121180.md","text":"https://secwatch.observer/filing/0001104659-25-121180.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925121180/0001104659-25-121180-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925121180/tm2533533d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:14:14.232210+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}